Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations
Clinical trial NCT03316560 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03316560
- Sponsor
- Beacon Therapeutics
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-16
- Primary completion
- 2023-11-09
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.